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Separation of etodolac enantiomers by capillary
electrophoresis. Validation and application of the
chiral method to the analysis of commercial
formulations
Separation of etodolac enantiomers, which exhibit different biological activity and
pharmacokinetic profiles, has been achieved using the randomly substituted
(2-hydroxy)propyl-b-cyclodextrin (HP-b-CD) as chiral selector in capillary electropho-
resis. The selection of this CD was made after screening of different CD derivatives of
neutral and anionic nature. The effect on the enantioresolution of the buffer con-
centration and of the degree of substitution (DS) and concentration of the CD as well as
of instrumental parameters, such as the capillary temperature and the separation
voltage, were studied. The highest resolution of etodolac enantiomers was around 2.5
using 100 mM phosphate buffer (pH 7.0) with 20 mM HP-b-CD (DS, 4.2) and UV
detection at 225 (10) nm with a reference wavelength at 360 (50) nm. Validation of the
chiral method in terms of selectivity, linearity, precision (instrumental repeatability,
method repeatability, intermediate precision), and the limits of detection and quantita-
tion allowed to evaluate its quality to the analysis of etodolac enantiomers in different
pharmaceutical preparations containing racemic etodolac.
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1 Introduction
Etodolac (Fig. 1) is a nonsteroidal anti-inflammatory drug
(NSAID) that exhibits anti-inflammatory, analgesic, and
antipyretic activities in animal models. This drug is
marketed as a racemic mixture of etodolac in which the
S-form is biologically active [1]. However, it has been
reported very recently that the R-enantiomer exhibits
pharmacological activity in patients suffering from leuke-
mia (B-cell chronic lymphocytic leukemia) [2]. Additional-
ly, the more extensive binding of S-etodolac compared to
the R-form to human serum albumin under physiological
conditions has also been reported [3, 4]. On the other
hand, enantioselectivity was reflected in the pharmacoki-
Figure 1. Basic structure of eto-
dolac ((6)-1,8-diethyl-1,3,4,9-
tetrahydropyrano-[3,4-b]indole-
1-acetic acid); (*) indicates the
chiral center.
netics of etodolac enantiomers since the plasma con-
centrations of the R-enantiomer greatly exceeded those
of the S-form [5, 6].
Several methods for the separation of etodolac enantio-
mers by high-performance liquid chromatography (HPLC)
have been reported showing the interest of the develop-
ment of chrial methods for the analysis of etodolac [7–10].
However, the capability of capillary electrophoresis (CE)
as separation technique for drug enantiomers is widely
recognized nowadays. Hundreds of scientific papers, a
wide number of reviews, several dedicated issues of
international journals [11–15] and even a book [16] have
been published reporting a large number of enantiomeric
separations of drugs by CE. However, until now, very few
methods for the baseline separation of etodolac enantio-
mers have been reported. Using vancomycin as chiral
selector, Fanali et al. [17] achieved the separation of the
enantiomers of etodolac in about 12 min and detected
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them by mass spectrometry with electrospray ionization.
Vancomycin is a glycopeptide-type macrocyclic antibiotic
with a limited pH working range (4 , pH , 8), adsorbs to
the wall of untreated fused-silica capillaries and has
strong absorption in the UV-Vis region. On the other hand,
a permethylated g-CD was used as chiral selector by
Mayer and Schurig [18] in capillary electrochromato-
graphy. They showed the usefulness of open-tubular
columns for the enantioseparation of NSAIDs including
etodolac. However, only with the permethylated g-CD
(Chirasil-Dex) it was possible to achieve a resolution of
1.6 for etodolac enantiomers in 30 min.
Our goal was to develop a chiral separation method by CE
using cyclodextrins (CDs) as chiral selectors due to their
potential for chiral separations, commercial availability,
stability, and easy use in comparison with other chiral
selectors as, for example, macrocyclic antibiotics or pro-
teins, which present similar practical problems. Then, in
this work, we have made a screening of different CD
derivatives of neutral and anionic nature to select the
most appropriate chiral selector for the enantioresolution
of etodolac by CE. With the slected chiral selector, effect
on the enantioresolution of the buffer concentration,
degree of substitution (commercial origin) of the chiral
selector, and concentration of the CD, as well as instru-
mental parameters, such as temperature and the
separation voltage, have been studied to achieve the best
resolution of etodolac enantiomers. Finally, the validation
of the chiral method and its use to quantify the amount of
etodolac in different pharmaceutical preparations have
also been performed.
2 Materials and methods
2.1 Reagents and samples
All reagents employed for the preparation of the separa-
tion buffers were of analytical grade. Disodium hydrogen
phosphate hydrate and sodium acetate were supplied
by Panreac (Barcelona, Spain). Dimethyl sulfoxide
(DMSO) was from Scharlab (Barcelona, Spain). Sodium
hydroxide, sodium dihydrogen phosphate dihydrate, and
ortophosphoric acid were from Merck (Darmstadt, Ger-
many). b-Cyclodextrin (b-CD), randomly methylated
b-cyclodextrin (RAMEB, degree of substitution (DS), aver-
age number of substituents on one cyclodextrin ring
,12–14), 2-hydroxypropylated-b-cyclodextrin (HP-b-
CD, DS,4.2), carboxymethylated b-cyclodextrin (CM-b-
CD, DS,3), and succinylated b-cyclodextrin (Succ-b-
CD, DS, 3) were purchased from Fluka (Buchs, Switzer-
land). (2-Hydroxy)-buten-3-yl-b-cyclodextrin (HBen-b-
CD, DS,5), carboxyethylated-b-cyclodextrin (CE-b-
CD, DS, 3), carboxyethylated g-cyclodextrin (CE-g-CD,
DS, 4), acetylated b-cyclodextrin (Ac-b-CD, DS,7),
acetylated g-cyclodextrin (Ac-g-CD, DS, 7), carbox-
ymethylated g-cyclodextrin (CM-g-CD, DS, 3), g-cyclo-
dextrin (g-CD), and HP-b-CD (DS,3) were from Cyclolab
(Budapest, Hungary). In addition, HP-b-CD (DS,4.7) and
RAMEB (DS,10.5–14.7) were also obtained from Sigma
(Madrid, Spain). Water used to prepare solutions was pu-
rified with a Milli-Q system from Millipore (Bedford, MA,
USA). All solutions were filtered prior to use through
0.45 mm pore size disposable nylon filters from Sugelabor
(Madrid, Spain). Etodolac was from Sigma. The pharma-
ceutical tablets analyzed were obtained in a pharmacy of
Ismira (Turkey). Table 1 shows the composition of these
formulations.
Table 1. Composition of the three different commercial
formulations analyzed
Commercial
formulation
Composition
Tablet A Etodolac (200 mg per tablet), Fe2O3 and TiO2
Tablet B Etodolac (300 mg per tablet), Fe2O3, FeO, and TiO2
Tablet C Etodolac (300 mg per tablet), Fe2O3 and TiO2
2.2 Apparatus
All experiments were performed on a HP3D CE system
(Hewlett-Packard, Waldbronn, Germany) equipped with
an on-column diode array detector (DAD). Instrument
control and data acquisition was performed with the HP
3D-CE ChemStation software. Separations were per-
formed on uncoated fused-silica capillaries of 50 mm ID
and 375 mm OD, purchased from Composite Metal Ser-
vices (Worcester, England). Capillaries had a total length
of 58.5 cm and 50 cm to the detector. The capillary tem-
perature was 157C and UV detection was performed at
225 nm with a bandwidth of 10 nm using a reference
wavelength of 360 nm with a bandwidth of 50 nm and a
response time of 0.3 s. To adjust the pH of the separation
buffers, a 744 pH-meter from Metrohm (Herisau, Switzer-
land) was used.
2.3 Procedures
Before its first use, a new capillary was flushed (1 bar) with
1 M NaOH for 30 min, followed by 30 min with water and
60 min with buffer. Between introduction of samples, the
capillary was conditioned with 0.1 M NaOH for 1 min fol-
lowed by the separation buffer for 2 min. Injections were
made by pressure (50 mbar for 3 s of sample followed by
50 mbar for 3 s of buffer), and the applied voltage was
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20 kV. Buffer separation solutions were prepared by dis-
solving the same amount of the acid and basic compo-
nents in order to get the desired pH, the pKa of the
selected acid. The appropriate amount of each CD was
weighed and dissolved into these buffer solutions at a
final concentration of 20 mM. Stock solutions were pre-
pared by dissolving the appropriate amount of etodolac in
DMSO to achieve a final concentration of 2000 mg/L.
These solutions were diluted in 1:1 v/v water/DMSO to
get diluted solutions with concentrations of etodolac be-
tween 10 and 200 mg/L (5 and 100 mg/L of each enan-
tiomer). Sample solutions of the three commercial for-
mulations analyzed were prepared by crushing and mix-
ing homogeneously five tablets of each commercial
formulation and weighing about 0.1 g (0.11–0.13 g) of the
resultant powder which was dissolved in DMSO at a final
concentration of 5000 mg/L. These sample solutions
were diluted 1:1 v/v in water/DMSO to get solution con-
centrations of 100 mg/L. All solutions (buffers, standards,
and samples) were filtered through 0.45 mm pore size
nylon filter membranes and sonicated before use.
2.4 Data treatment
Resolution was obtained from the ChemStation software
using the equation Rs = 1.18 t22t1/w1/2, 11w1/2, 2 where t1
and t2 are the migration times of etodolac enantiomers
and w1/2,1 , w1/2,2 are their peak widths at half height. Lim-
its of detection (LODs; 3sa/b) and quantitation (LOQs,
10sa/b) were determined from the standard error of the
intercept (sa) and the slope (b) of the calibration curve
obtained by analysis of variance (ANOVA) [19]. Control
graphs elaborated for stability studies were made plotting
corrected peak areas as a function of time. The central
values, X, were calculated as the averaged value of six
repeated runs, and the control limits (which enable to
visualize the values in and out of control) were calculated
as X 6 3s where s is the standard deviation of the six
replicate values [20]. Experimental data analysis and pa-
rameters were calculated using Excel Microsoft XP and
Statgraphics Plus Version 5.0 softwares.
3 Results and discussion
3.1 Method optimization
The crucial step to achieve an enantiomeric separation is
the choice of the chiral selector. CDs are the favourite
chiral selectors in CE and they have shown to separate
the enantiomers of a huge amount of chiral drugs. Due to
their availability, stability, and potential, we selected dif-
ferent CD derivatives of neutral and anionic nature (see
Table 2) for screening their capability as chiral selectors for
etodolac enantiomers. All these CDs were used in 50 mM
phosphate buffer at pH 7.0. This buffer was used because
it enabled the larger difference between the EOF and eto-
dolac signals (the pKa of etodolac is 4.65). In addition, the
buffer pH is similar to physiological conditions which is
desirable for pharmacokinetic studies where biological
fluids at this pH (e.g., blood) may be analyzed.
As shown in Table 2, the anionic cyclodextrins CM-g-CD,
CM-b-CD, CE-g-CD, CE-b-CD, and Succ-b-CD and the
neutral cyclodextrins b-CD, RAMEB from Sigma, Ac-b-
CD, and Ac-g-CD (all of them at a concentration of 20 mM)
did not show enantioresolution power for etodolac. With
20 mM RAMEB from Fluka or HBen-b-CD poor enantio-
resolutions were observed (Rs , 0.7). The highest enan-
tioresolutions were obtained for the neutral HP-b-CD and
g-CD at a concentration of 20 mM in phosphate buffer at
pH 7.0 (see Table 2). As a consequence, we selected HP-
b-CD as chiral selector for the separation of etodolac
enantiomers because it is less expensive than g-CD.
Table 2. Enantioresolutions (Rs) of etodolac enantiomers
obtained with the different CD derivatives stud-
ied at a 20 mM concentration
CD (commercial supplier) Enantioresolution
Neutral CDs b-CD (Fluka) 2
RAMEB (Sigma) 2
RAMEB (Fluka) 1
HP-b-CD (Cyclolab) 11
HBen-b-CD (Cyclolab) 1
Ac-b-CD (Cyclolab) 2
g-CD (Cyclolab) 11
Ac-g-CD (Cyclolab) 2
Anionic CDs Succ-b-CD (Fluka) 2
CM-b-CD (Fluka) 2
CE-b-CD (Cyclolab) 2
CM-g-CD (Cyclolab) 2
CE-g-CD (Cyclolab) 2
2,Rs,0; 1,Rs , 0.7; 11, 0.7  Rs  1
With the selected CD, the influence on enantiomeric res-
olution of the temperature and separation voltage was
studied to choose the most appropriate values of these
parameters.The variation of the resolution for etodolac
enantiomers as a function of the capillary temperature in
the range of 15–457C. showed that the resolution gradu-
ally decreases as the temperature increases. This effect
was observed previously with the same CD derivative by
our research group [21] and could be attributed to the
increase in the stability of selector-selectand complexes
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that takes place when the temperature is decreased [16,
21, 22]. Therefore, all subsequent separations were per-
formed at 157C. However, a low influence of the separa-
tion voltage on the enantioresolution of drugs is generally
obtained. For etodolac enantiomers a similar enantio-
resolution was obtained for 15 and 20 kV whereas the
resolution decreased for 30 kV. Since the migration times
decreased when increasing the applied voltage, 20 kV of
separation voltage was used in our experiments.
The effect of the buffer concentration on the separation of
etodolac enantiomers was investigated by using different
concentrations (40, 50, 80, and 100 mM) phosphate buffer
containing 20 mM HP-b-CD. As it can be seen in Fig. 2,
there is a linear increment of the enantioresolution with
the phosphate buffer concentration from 40 to 100 mM.
This can be explained because when the buffer con-
centration increases the solute-wall interactions and the
undesirable effects of electrodispersion are minimized
[16]. Therefore, 100 mM phosphate buffer at pH 7
(, 140 mA) was used for further experiments.
The influence of the concentration and the degree of
substitution of HP-b-CD (commercial origin) in the
selected buffer was also studied. The commercial origin
of the chiral selector in the separation buffer was found to
be a very decisive factor influencing the enantiomeric
resolution of the etodolac enantiomers. This is because
Figure 2. Effect of the buffer concentration on the enan-
tioresolution of etodolac for a phosphate buffer (pH 7)
with 20 mM HP-b-CD (Cyclolab) as chiral selector. CE
conditions: temperature, 157C; untreated fused-silica
capillary, 58.5 cm (50 cm to the detector window)650 mm
ID; applied voltage, 20 kV; injection, 50 mbar63 s. UV
detection at 230 nm.
HP-b-CD is a randomly substituted CD manufactured in a
different way by the three different suppliers which
provide different DSs (see Section 2). Thus, depending on
the DS, the substitution patterns can be different and
even side chain substitution (e.g., 2-(2’-hydroxy)propoxy)
propyl substituents) is possible. In addition, the DS
depends on the chemical reaction (used base, low/high
temperature) and large differences between batches and
production sites may be obtained under some conditions.
Due to these problems, a trend in chiral analysis by CE is
the use of single-isomer CDs, which are able to achieve
higher reproducibility and selectivity than randomly
substituted CDs [23]. However, it is important to note that
HP-b-CD, which has been shown to be the best chiral
selector for etodolac, is not a single isomer (Cyclolab
produces the single isomer monoHp-b-CD but its aque-
ous solutility is very poor, , 0.05 g/100 cm3, being not
useful in aqueous CE). For this reason, we studied the
effect of the concentration of this CD from three different
commercial suppliers on the resolution of etodolac enan-
tiomers. This study was performed because the con-
centration of the chiral selector affects directly the chiral
properties [21, 24]. As can be seen in Fig. 3, when varying
the concentration of HP-b-CD of the three different com-
mercial origins from 10 to 60 mM, the maximum enantio-
resolution for etodolac was observed at a 20 mM CD con-
centration. In addition, HP-b-CD from Fluka (DS , 4.2)
gets always the best enantioresolution values for all the
concentrations studied. As a consequence, this con-
centration of the HP-b-CD (DS , 4.2) was chosen for the
enantiomeric separation of etodolac.
Figure 3. Influence of the concentration and the DS
(commercial origin) effect of the HP-b-CD in 100 mM
phosphate buffer (pH 7) on the enantioresolution of eto-
dolac. CE conditions as in Fig. 2.
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The detection conditions for etodolac enantiomers were
also studied in this work. As it is known, the response time
of the detector affects the baseline noise and the enan-
tioresolution. In this case, an increase in the response
time from 0.1 to 0.3 s leads to a decrease in the noise
(from 0.7961024 to 0.4361024 A.U.) whereas enantio-
resolution was maintained (Rs 2.1). However, for a re-
sponse time of 1.0 s although the noise decreased, the
data acquired was not enough to show any enantio-
resolution. As a result, a response time of 0.3 s was used
to afford the lowest noise (highest signal-to-noise ratio,
S/N) with an adequate resolution. In addition, the optimi-
zation of the analytical wavelength value, the reference
wavelength, and the bandwidth (it will be indicated within
parentheses) of those wavelengths was performed. Pre-
liminary studies were carried out at an analytical wave-
length of 230 nm (4) [18, 25] with the lowest possible
bandwidth and without reference wavelength. From the
absorption spectrum of etodolac it was observed that the
absorption band of maximum absorption is around
230 nm. Then 225, 230, and 235 nm were used as ana-
lytical wavelengths obtaining the highest S/N at 225 nm.
At this wavelength, the bandwidth and the reference
wavelength were studied. The lowest noise and higher
S/N were obtained using 225 nm (10) and a reference
wavelength of 360 nm (50). The electropherogram shown
in Fig. 4 for the separation of etodolac enantiomers was
obtained under these detection conditions. A resolution
.2 for etodolac enantiomers can be observed when
using 100mM phosphate buffer (pH 7.0) with 20 mM HP-b-
CD (DS , 4.2).
Figure 4. Electropherogram corresponding to the
separation of etodolac enantiomers using 20 mM HP-b-
CD (Fluka) in 100 mM phosphate buffer (pH 7). CE condi-
tions: UV detection at 225 (10) nm and reference at 360
(50) nm; time response of detector, 0.3 s. Other conditions
as in Fig. 2.
3.2 Method validation
Prior to the validation of the chiral method developed for
etodolac the preconditioning of the capillary and the pro-
cedure for sample injection (with or without plug) were
studied. A preconditioning with the separation buffer or
with 0.1 M NaOH followed by separation buffer by pres-
sure (1 bar for 2 min) or voltage (2 kV) showed that a volt-
age stage did not improve the precision (measured as
RSD for migration times for six replicates of a standard
solution). However, the use of NaOH followed of back-
ground electrolyte (BGE) gave the best precision without
any loss of enantioresolution. After injection of the sample
(50 mbar for 3 s), a plug (50 mbar for 3 s) of DMSO or
separation buffer was injected. An improvement of the
precision without loss in enantioresolution was observed
when a plug of BGE after sample injection was used (with
DMSO a decrease in the enantioresolution and precision
was obtained).
The proposed analytical method for the analysis of eto-
dolac enantiomers was validated by evaluating the qual-
ity, reliability, and consistency of its results. Nevertheless,
prior to the validation, a study on sample stability was
carried out. Etodolac concentrations of 10 and 100 mg/L
(5 and 50 mg/L of each enantiomer) were prepared and
then injected every day for a total of five days. As it can be
seen in Fig. 5, the corrected peak areas obtained for the
two independent samples analyzed (samples A and B) are
included into the control limits.
The validation of the chiral CE method was made by
studying the precision, linearity, LODs and LOQs, and
selectivity for different commercial pharmaceutical
tablets. Precision was evaluated considering the instru-
mental and method repeatability as well as the inter-
mediate precision. Instrumental repeatability was deter-
mined from six repeated injections of two standard solu-
tions at two different concentration levels (10 and 100mg/L
etodolac). In both cases, RSD values for corrected peak
areas below 5% were obtained (Table 3). The method
repeatability was assessed with six replicate standard
solutions of 10 and 100 mg/L etodolac injected by tripli-
cate on the same day. RSD values for both standard
solutions were lower than 6.7% for corrected peak areas
(Table 3). The intermediate precision of the method was
calculated for three freshly prepared standard solutions of
etodolac containing 10, 50, and 100 mg/L and injected by
triplicate for five consecutive days. Table 3 shows that in
this case the RSD value for corrected peak areas was
lower than 8.2%.
The linearity was studied plotting corrected peaks areas
(Ac) as a function of analyte concentrations (c) in mg/L.
Five standard solutions containing racemic etodolac from
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Figure 5. Study of the sample stability with 5 and 50 mg/L solutions of etodolac enantiomers using 20 mM HP-b-CD (DS,
4.2) in 100 mM phosphate buffer (pH 7). Injection, sample 50 mbar63 s with a plug of BGE at 50 mbar63 s. Other condi-
tions as in Fig. 4.
Table 3. Precision of the chiral method developed for
etodolaca)
Etodolac
concentration
(mg/L)
RSD (%) peak area
First
enantiomer
Second
enantiomer
Instrumental repeatability
(n = 6)
10 4.1 4.3
100 4.9 4.7
Method repeatability
(n = 6)
10 5.8 5.3
100 6.7 5.4
Intermediate precision
(n = 15)
10 7.2 8.2
50 7.3 7.6
100 8.1 8.2
a) Experimental conditions as in Fig. 4
10 to 200 mg/L (each one injected in triplicate) were con-
sidered. The chiral method enabled to study separately
each enantiomer, which concentrations ranged from 5 to
100 mg/L for each enantiomer. By ANOVA we confirmed
that experimental data fit properly to linear models for
each one of the enantiomers (the lack of fit was always
statistically smaller than the pure error, p-value 0.51 and
0.45 for enantiomers). The linear equations obtained were
Ac = 0.0668 c – 0.07 (sa = 0.13; sb = 0.0021; r = 0.994) for
the first-migrating enantiomer and Ac = 0.0648 c – 0.07
(sa = 0.13; sb = 0.0021, r = 0.994) for the second-migrating
enantiomer, where sa is the standard error of the intercept,
sb is the standard error of the slope, and r is the correlation
coefficient. From calibration line parameters, LODs and
LOQs for etodolac enantiomers were calculated. For both
enantiomers the LOD was 5.8 mg/L and the LOQ was
19.4 mg/L.
An adequate selectivity for the analysis of three commer-
cial preparations was obtained with the chiral method
developed for etodolac. Figure 8 shows the enantiomeric
separation of etodolac for three different commercial
tablets. It can be observed that the enantioresolution of
etodolac is good and there are no evidence of inter-
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Figure 6. Electropherogram corresponding to the
separation of etodolac enantiomers in three different
commercial formulations, using 20 mM HP-b-CD (DS ,
4.2) in 100 mM phosphate buffer (pH 7). CE conditions as
in Fig. 4.
ferences due to the other components present in the
commercial formulation (see Table 1). In addition, peaks
corresponding to etodolac enantiomers in these samples
were confirmed by comparison of their UV absorption
spectra with those of the standard. It should be taken into
account that migration times of tablets are shorter than
those of standard solutions. This can be explained by the
presence of other components in the pharmaceutical for-
mulations (few minor oxides as illustrated in Table 1)
which affects the EOF. It is already known that other
components, such as cellulose derivatives, frequently
present in tablets, affect the EOF, thereby modifying the
migration times in a significant way [26]. However, this
problem is easily solved using corrected migration times
and areas, as it has been done in this work.
Finally, Table 4 shows the amount of etodolac calculated
for the three commercial formulations analyzed. The
quantification of etodolac enantiomers confirms that the
drug is present in tablets as racemate (1:1 mixture). In
addition, results obtained show that the etodolac amount
present in tablets is inside the range of the determined
amount. Therefore, a good agreement between the
amount of etodolac determined by the chiral CE method
developed and that declared in the label of the pharma-
ceutical preparation was observed.
4 Concluding remarks
In this work, the possibilities of the randomly substituted
HP-b-CD as chiral selector for etodolac are presented.
Although different enantioresolutions were obtained for
this CD with different DSs depending on the supplier
(Cyclolab, Fluka, or Sigma), the HP-b-CD of Fluka (DS ,
4.2) allowed to obtain a reproducible resolution. 2 under
the applied experimental conditions (100 mM phosphate
buffer, pH 7.0, with 20 mM HP-b-CD for the CE separation,
and UV detection at 225 (10) nm with reference at 360
(50) nm). The chiral CE method using the selected condi-
tions was validated to show the quality, reliability, and
consistency of its results. Good performance with regard
to linearity, instrumental repeatability, method repeat-
ability, intermediate precision, and selectivity was
achieved. LODs of 5.8 mg/L and LOQs of 19.4 mg/L were
obtained for each etodolac enantiomers. The validated
method was applied to determine the amount of etodolac
enantiomers in three different commercial tablets, being
suitable for such purposes.
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Table 4. Averaged amount of etodolac enantiomers and total etodolac measured in the three different commercial
formulations analyzeda)
Commercial
formulation
Weight (mg)
first enantiomer
6 t s/n1/2
Weight (mg)
second enantiomer
6 t s/n1/2
Total weight
(mg)
6 t s/n1/2
RSD (%)
Corrected
peak area
Total labeled
weight (mg)
Tablet A 105.26 5.9 105.36 6.2 210.56 12.1 7.6 200
Tablet B 157.46 8.2 157.36 8.5 314.76 16.8 7.1 300
Tablet C 156.26 7.5 156.96 8.8 313.16 16.2 6.9 300
a) s is the standard deviation, t = 2.262 (for a confidence linear range of 95%), and n = 9.
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